Lauren Darrigues
YOU?
Author Swipe
View article: Predictive factors for breast conserving surgery after neoadjuvant chemotherapy in breast cancer
Predictive factors for breast conserving surgery after neoadjuvant chemotherapy in breast cancer Open
Several factors were independently associated with breast conserving surgery, including: unifocality, clinical complete response (cCR) and clinical tumor less than 5 cm.
View article: Impact of neoadjuvant immunotherapy on postoperative complications in oncoplastic breast cancer surgery
Impact of neoadjuvant immunotherapy on postoperative complications in oncoplastic breast cancer surgery Open
View article: Time-to-pregnancy in patients with previous breast cancer and unexposed women: a prospective exposed-unexposed cohort study
Time-to-pregnancy in patients with previous breast cancer and unexposed women: a prospective exposed-unexposed cohort study Open
View article: Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC).
Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC). Open
552 Background: NAC +/- immune checkpoint inhibitors is the standard of care for most early-stage TNBC patients. After NAC and breast surgery, adjuvant treatment decisions rely on pathological complete response (pCR) status, which does not…
View article: Magnetic surgical marker navigation for excision of non-palpable ultrasound visible breast lesions: first 200 cases in a French cancer center
Magnetic surgical marker navigation for excision of non-palpable ultrasound visible breast lesions: first 200 cases in a French cancer center Open
Wire guided localization is widely used as the standard method of pre-operative localization of breast lesions. The aim was to assess outcomes following the introduction of a novel non-wire guided, magnetic surgical marker navigation syste…
View article: Prophylaxie chirurgicale mammaire chez les patientes à très haut risque de cancer du sein
Prophylaxie chirurgicale mammaire chez les patientes à très haut risque de cancer du sein Open
Prophylactic bilateral mastectomy is an effective strategy for reducing the risk of breast cancer, particularly in patients with pathogenic BRCA gene variants. Personalized assessment, detailed information on risks and impacts, and the use…
View article: A Prospective Exposed-Unexposed Cohort Study Comparing Time-to-Pregnancy in Patients with Previous Breast Cancer and Controls from a Collaborative Research Network: Results after Three Years of Follow-Up
A Prospective Exposed-Unexposed Cohort Study Comparing Time-to-Pregnancy in Patients with Previous Breast Cancer and Controls from a Collaborative Research Network: Results after Three Years of Follow-Up Open
View article: Sex-related differences in oncological surgery and postoperative outcomes: comprehensive, nationwide study in France
Sex-related differences in oncological surgery and postoperative outcomes: comprehensive, nationwide study in France Open
Background The main objective of this study was to undertake an exhaustive investigation of sex-related differences in cancer surgery. Methods This observational study used data from the French national health insurance system database cov…
View article: Successful excision of non–palpable breast lesions using a magnetic surgical marker navigation system in a specialized French oncologic center
Successful excision of non–palpable breast lesions using a magnetic surgical marker navigation system in a specialized French oncologic center Open
Wire guided localization is widely used as the standard method of pre-operative localization of breast lesions. The aim was to assess outcomes following the introduction of a novel non wire guided, magnetic surgical marker navigation syste…
View article: Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib
Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib Open
View article: Effects of gender and socio-environmental factors on health-care access in oncology: a comprehensive, nationwide study in France
Effects of gender and socio-environmental factors on health-care access in oncology: a comprehensive, nationwide study in France Open
None.
View article: Table S3 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table S3 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Table S3
View article: Table S4 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table S4 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Table S4
View article: Supplementary Data from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Supplementary Data from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
supplementary figures
View article: Supplementary Table 11 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Supplementary Table 11 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Supplementary Table 11
View article: Supplementary Data from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Supplementary Data from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
supplementary material
View article: Table S3 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table S3 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Table S3
View article: Table S1 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table S1 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Table S1
View article: Table S2 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table S2 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Table S2
View article: Table S9 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table S9 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Table S9
View article: Table S5 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table S5 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Table S5
View article: Data from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Data from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Purpose:High levels of tumor-infiltrating lymphocytes (TIL) before neoadjuvant chemotherapy (NAC) are associated with higher pathologic complete response (pCR) rates and better survival in triple-negative breast cancer (TNBC) and HER2
View article: Table S6 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table S6 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Table S6
View article: Table S6 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table S6 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Table S6
View article: Table S7 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table S7 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Table S7
View article: Table S8 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table S8 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Table S8
View article: Table S9 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table S9 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Table S9
View article: Table S10 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table S10 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Table S10
View article: Table S7 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table S7 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Table S7
View article: Table S4 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Table S4 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Open
Table S4